Impact of methotrexate‐dosing regimens for GVHD prophylaxis on clinical outcomes of HLA ‐matched allogeneic HSCT
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70213 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Tomotaka Suzuki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Methotrexate, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, HLA Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Severe graft‐versus‐host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo‐HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)‐dosing regimens for GVHD prophylaxis in patients undergoing human leucocyte antigen (HLA)‐matched allo‐HSCT: a low‐dose 3‐day regimen (Ld3:10 mg/m 2 on day 1, 7 mg/m 2 on days 3 and 6), a low‐dose 4‐day regimen (Ld4: Ld3 with an additional 7 mg/m 2 on day 11) and an original‐dose 3‐day regimen (Od3: 15 mg/m 2 on day 1, 10 mg/m 2 on days 3 and 6). Among 2537 analysed patients, Ld3 was the most commonly used regimen. Multivariate analyses showed no significant differences in the cumulative incidence of grade II–IV acute GVHD among regimens. However, Od3 was associated with an increased risk of grade III–IV acute GVHD, and Ld4 was linked to delayed neutrophil engraftment. This study is the first large‐scale retrospective analysis of the impact of different MTX‐dosing regimens on the outcomes of HLA‐matched allo‐HSCT, providing valuable insights into optimal MTX‐dosing strategies in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Hematology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Hematology, Kobe City Medical Centre General Hospital, Kobe, Japan.
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
- Division of Hematology, Jichi Medical University Saitama Medical Centre, Saitama, Japan.
ORCID-Profile: Tomotaka Suzuki, Tomoyasu Jo, Kota Yoshifuji, Tadakazu Kondo, Yoshinobu Kanda, Noboru Asada, Shuichi Ota, Makoto Yoshimitsu, Yoshiko Atsuta, Junya Kanda
Zitieren
APA
Suzuki, T., Jo, T., Yoshifuji, K., Kondo, T., Doki, N., Kanda, Y., Nishida, T., Onishi, Y., Asada, N., Fukuda, T., Sawa, M., Hasegawa, Y., Serizawa, K., Ota, S., Tanaka, M., Yoshimitsu, M., Atsuta, Y., & Kanda, J. (2026). Impact of methotrexate‐dosing regimens for GVHD prophylaxis on clinical outcomes of HLA ‐matched allogeneic HSCT. British Journal of Haematology. https://doi.org/10.1111/bjh.70213
Vancouver
Suzuki T, Jo T, Yoshifuji K, Kondo T, Doki N, Kanda Y, et al. Impact of methotrexate‐dosing regimens for GVHD prophylaxis on clinical outcomes of HLA ‐matched allogeneic HSCT. British Journal of Haematology. 2026. doi:10.1111/bjh.70213
BibTeX
@article{Suzuki2026,
author = {Suzuki, Tomotaka and Jo, Tomoyasu and Yoshifuji, Kota and Kondo, Tadakazu and Doki, Noriko and Kanda, Yoshinobu and Nishida, Tetsuya and Onishi, Yasushi and Asada, Noboru and Fukuda, Takahiro and Sawa, Masashi and Hasegawa, Yuta and Serizawa, Kentaro and Ota, Shuichi and Tanaka, Masatsugu and Yoshimitsu, Makoto and Atsuta, Yoshiko and Kanda, Junya},
title = {Impact of methotrexate‐dosing regimens for GVHD prophylaxis on clinical outcomes of HLA ‐matched allogeneic HSCT},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70213}
}
EUVIMED